Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal)

  • Technology appraisal
  • TA652
  • Published: 

This guidance has been updated and replaced by NICE technology appraisal guidance 816.